CA3227713A1 - 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof - Google Patents

8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof Download PDF

Info

Publication number
CA3227713A1
CA3227713A1 CA3227713A CA3227713A CA3227713A1 CA 3227713 A1 CA3227713 A1 CA 3227713A1 CA 3227713 A CA3227713 A CA 3227713A CA 3227713 A CA3227713 A CA 3227713A CA 3227713 A1 CA3227713 A1 CA 3227713A1
Authority
CA
Canada
Prior art keywords
mmol
compound
alkyl
cancer
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227713A
Other languages
English (en)
French (fr)
Inventor
Yaobang CHENG
Yafei HUANG
Juan Zhou
Yonghui Wang
Wyatt Wei CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Littdd Medicines Ltd
Original Assignee
Littdd Medicines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Littdd Medicines Ltd filed Critical Littdd Medicines Ltd
Publication of CA3227713A1 publication Critical patent/CA3227713A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3227713A 2021-07-27 2022-07-26 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof Pending CA3227713A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110860428.3 2021-07-27
CN202110860428 2021-07-27
CN202210779302.8 2022-07-01
CN202210779302 2022-07-01
PCT/CN2022/107932 WO2023005928A1 (zh) 2021-07-27 2022-07-26 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途

Publications (1)

Publication Number Publication Date
CA3227713A1 true CA3227713A1 (en) 2023-02-02

Family

ID=85060847

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3227713A Pending CA3227713A1 (en) 2021-07-27 2022-07-26 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof

Country Status (10)

Country Link
US (1) US20240294550A1 (cg-RX-API-DMAC7.html)
EP (1) EP4378943A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527044A (cg-RX-API-DMAC7.html)
KR (1) KR20240041354A (cg-RX-API-DMAC7.html)
CN (2) CN115677730B (cg-RX-API-DMAC7.html)
AU (1) AU2022316931A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227713A1 (cg-RX-API-DMAC7.html)
IL (1) IL310412A (cg-RX-API-DMAC7.html)
TW (1) TW202321256A (cg-RX-API-DMAC7.html)
WO (1) WO2023005928A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202602891A (zh) * 2024-03-28 2026-01-16 大陸商勵締(杭州)醫藥科技有限公司 具有mTOR抑制活性的有機化合物及其用途
TW202545519A (zh) * 2024-05-15 2025-12-01 俄羅斯聯邦商拜奧卡德聯合股份公司 共濟失調毛細血管擴張症和Rad3相關激酶抑制劑
WO2026037494A1 (en) * 2024-08-14 2026-02-19 Eracal Therapeutics Ltd. New compounds and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
AU2017269726B2 (en) 2016-05-24 2021-10-14 Merck Patent Gmbh Tricyclic heterocylic derivatives
AU2019334264B2 (en) * 2018-09-07 2024-10-31 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
KR20210097124A (ko) * 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
CN111848605B (zh) 2019-04-30 2023-05-02 四川科伦博泰生物医药股份有限公司 一种取代吡啶并[3,4-b]吡嗪-2(1H)-酮化合物、其制备方法和用途
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
AU2021321905A1 (en) * 2020-08-07 2023-04-13 Antengene Discovery Limited ATR inhibitors and uses thereof

Also Published As

Publication number Publication date
TW202321256A (zh) 2023-06-01
US20240294550A1 (en) 2024-09-05
IL310412A (en) 2024-03-01
AU2022316931A1 (en) 2024-03-14
EP4378943A1 (en) 2024-06-05
EP4378943A4 (en) 2024-12-11
CN118043325A (zh) 2024-05-14
CN115677730A (zh) 2023-02-03
WO2023005928A1 (zh) 2023-02-02
CN115677730B (zh) 2024-11-12
JP2024527044A (ja) 2024-07-19
KR20240041354A (ko) 2024-03-29

Similar Documents

Publication Publication Date Title
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
CN114423756B (zh) 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
US20240270753A1 (en) Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof
JP2025532125A (ja) 新規なテトラヘテロサイクル化合物
WO2020181283A1 (en) Carboxamide-pyrimidine derivatives as shp2 antagonists
EP4705281A1 (en) Compounds for treating cancer
AU2014225155B2 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
CN115710266A (zh) 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
US11034696B2 (en) Compounds for inhibiting LRRK2 kinase activity
AU2022316931A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
AU2022345314B2 (en) Azaindazole macrocyclic compound and use thereof
CN116323562B (zh) 一类具有激酶抑制活性的化合物
WO2022253309A1 (zh) 取代的杂环化合物及其应用
JP2024527044A5 (cg-RX-API-DMAC7.html)
KR20250048262A (ko) 아자-퀴나졸린 화합물 및 사용 방법
US20240166640A1 (en) Heteroaryl derivative compounds, and uses thereof
CN119233974A (zh) 一种吲哚酮衍生物及其应用
TW202136267A (zh) Bruton酪胺酸激酶(BTK)抑制劑
CN116375712A (zh) 双吗啉取代的杂环化合物及其医药用途
EP3954680A1 (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
EA050883B1 (ru) 8-окса-3-азабицикло[3.2.1]октановые соединения или их соли, способ их получения и применение
WO2024216164A1 (en) N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer
EP4698531A1 (en) Pyrrolopyrazine compounds, preparation thereof and therapeutic uses thereof
CN121991057A (zh) Irak4靶向降解化合物及其应用
CN120731212A (zh) 作为egfr抑制剂的大环氨基吡啶化合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250721

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250721

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20260724

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20260724

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260724

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260724

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260806

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260806